The MIN-102 Placebo is supplied as an oral suspension with similar appearance to MIN-102 drug product. MIN-102 placebo oral suspension is packaged in an amber glass bottle with filled volume based on the required clinical dose.
MT-3-01
Phase 3 small_molecule active
Quick answer
The MIN-102 Placebo is supplied as an oral suspension with similar appearance to MIN-102 drug product. MIN-102 placebo oral suspension is packaged in an amber glass bottle with filled volume based on the required clinical dose. for Cerebral adrenoleukodystrophy (cALD) is a Phase 3 program (small_molecule) at Minoryx Therapeutics S.L. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Minoryx Therapeutics S.L.
- Indication
- Cerebral adrenoleukodystrophy (cALD)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active